VPRO News Friday, August 1, 2014 9:29:02 PM $VPRO
Post# of 37
Posted On: 08/01/2014 9:29:01 PM
VPRO News Friday, August 1, 2014 9:29:02 PM $VPRO
Court Recognizes Majority of Viropro Shareholders' Election of New Board of Directors
PR Newswire - Mon Jun 02, 7:36PM CDT
Viropro, Inc. (OTCBB: VPRO), a Nevada corporation that was formed to specialize in contract research, development and manufacturing of biotherapeutic proteins for the treatment of various diseases including cancer, diabetes, inflammation and hepatitis, today announced that it has a new Board of Directors as a result of an order of the Supreme Court of the State of New York in a challenge by a majority of the Viropro shareholders to the management of Viropro.
Viropro and Oncobiologics Sign Emerging Markets Biosimilars Deal
PR Newswire Europe - Mon Feb 25, 9:03AM CST
Viropro, Inc. and Oncobiologics, Inc. announced today the signing of a biosimilar collaboration agreement. Under the agreement, Viropro will have the rights to manufacture six monoclonal antibody products being developed by Oncobiologics for commercialization in more than 70 emerging market countries (excluding China). Viropro will have exclusive commercialization rights to the six biosimilars for Malaysia. In addition, the companies will co-manage Viropro's Penang, Malaysia Alpha Biologics biomanufacturing subsidiary. The alliance will seek regional partners to drive commercialization.
Court Recognizes Majority of Viropro Shareholders' Election of New Board of Directors
PR Newswire - Mon Jun 02, 7:36PM CDT
Viropro, Inc. (OTCBB: VPRO), a Nevada corporation that was formed to specialize in contract research, development and manufacturing of biotherapeutic proteins for the treatment of various diseases including cancer, diabetes, inflammation and hepatitis, today announced that it has a new Board of Directors as a result of an order of the Supreme Court of the State of New York in a challenge by a majority of the Viropro shareholders to the management of Viropro.
Viropro and Oncobiologics Sign Emerging Markets Biosimilars Deal
PR Newswire Europe - Mon Feb 25, 9:03AM CST
Viropro, Inc. and Oncobiologics, Inc. announced today the signing of a biosimilar collaboration agreement. Under the agreement, Viropro will have the rights to manufacture six monoclonal antibody products being developed by Oncobiologics for commercialization in more than 70 emerging market countries (excluding China). Viropro will have exclusive commercialization rights to the six biosimilars for Malaysia. In addition, the companies will co-manage Viropro's Penang, Malaysia Alpha Biologics biomanufacturing subsidiary. The alliance will seek regional partners to drive commercialization.
(0)
(0)Viropro Inc (VPRO) Stock Research Links
Scroll down for more posts ▼